Premium
Influence of liver cirrhosis on sertraline pharmacokinetics
Author(s) -
DÉMOLIS JEANLOUIS,
ANGEBAUD PASCAL,
GRANGÉ JEANDIDIER,
COATES PETER,
FUNCKBRENTANO CHRISTIAN,
JAILLON PATRICE
Publication year - 1996
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1046/j.1365-2125.1996.42817.x
Subject(s) - sertraline , pharmacokinetics , cmax , serotonin reuptake inhibitor , reuptake inhibitor , medicine , pharmacology , oral administration , cirrhosis , antidepressant , endocrinology , hippocampus
Sertraline is a serotonin reuptake inhibitor. The enhancement of serotoninergic transmission is associated with antidepressant activity. In order to determine the pharmacokinetics of sertraline in patients with chronic stable hepatic insufficiency, 10 patients were matched (age, weight, sex) with 10 healthy subjects in an open study. Each participant received a single capsule containing the equivalent of 100 mg sertraline base. Blood samples were taken during 264 h after administration for measurement of plasma concentrations of sertraline. The results confirm that the oral clearance of sertraline is reduced with a 1.7‐fold increase in C max and a significant prolongation in elimination half‐life in hepatically impaired patients